Docket Number:13A-1010911
Inventor:Che-Kun James Shen, Tsann-Long Su
IP Status:PCT, TW issue (I 536993)
Abstract:
Genomic mutation(s) or deletion(s) within globin gene loci results in functional deficiencies of hemoglobin expression, leading to hemoglobinopathic disease(s) with anemic syndrome. The β-thalassemia and sickle cell disease (SCD) are the two most common hemoglobinopathies; approximately 4.5% of the populations are suffering from the two diseases worldwide.1
Pharmacologic induction of HbF expression has been suggested to be a useful strategy to modulate anemia and related symptoms of these severe hemoglobinopathic patients. However, several side effects of HU have been reported, including leucopenia, thrombocytopenia, myelosuppression, and potential reproductive toxicity.10,11 In addition, about 25% of SCD patients are poor or non-responders for HU treatment.12 It is thus warranted to identify new agent, which is capable of inducing the expression of γ globin for treating hemoglobinopathies including β-thalassemia and sickle-cell disease.
We more recently found that several known naphthalimide derivatives display HbF-inducing effect. The symmetrical naphthalimide derivatives can be easily synthesized and obtained as a pure form in high yield. In addition, one can design and synthesize water-soluble analogues for evaluating their biological activity in animal model. We have studied the HbF-inductive effect of the newly synthesized naphthalimide derivatives and compared with that of S51021, HU, and NaB as well as their possible underlying mechanisms of action involved in the re-activation of γ globin gene expression. In sum, we have identified SS-2394, which is not a histone deacetylase inhibitor, as a lead compound for further developing as a novel agent for treating hemoglobinopathies such as β-thalassemia and sickle cell disease.
Fields of Application:
Drug Discovery for β-thalassemia and sickle cell disease
Advantages when compared to the existing technologies:
These compounds share the same core structure and they specifically activate the embryonic/fetal globin gene expression. Thus, we have discovered a class of chemical compounds with a common core structure that could be developed into a new generation of pharmaceuticals for curing the thalassemia and sickle cell disease.
Contact Person:Sue-Ming Chang / 886-2-2787-2600 / name4517@gate.sinica.edu.tw
